Chronic Myeloproliferative Disorders Completed Phase 2 Trials for Sargramostim (DB00020)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00053989Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic AnemiaTreatment
NCT00003408Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With CancerTreatment